ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendants materially overstated LifeMD's competitive position; (2) defendants were reckless in raising LifeMD's 2025 guidance, considering that they had not properly accounted for rising customer acquisition costs in LifeMD's RexMD segment, as well as for customer acquisition costs related to the sale of drugs designed to treat obesity, includi ...

NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and nine months ended September 30, 2025 after the close of the U.S. financial markets on November 6, 2025, and will host a conference call beginning at 4:30 p.m. Eastern time. Conference Call & Webcast Details Date:Thursday, November 6thTime:4:30 p.m. Eastern timeToll-Free Dial-In:800-245-3047International Dial-In:203-518 ...

Renowned Menopause and Hormone Specialist to Help Guide and Represent LifeMD’s Comprehensive and Personalized Care Offering for WomenNEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Tara Scott, MD, widely known as “The Hormone Guru,” as ambassador and clinical advisor for its comprehensive women’s health program. A respected physician, educator, and advocate, Dr. Scott will help champion LifeMD’s ...

整理 | GLP1减重宝典内容团队 CVS Health Ventures正悄然布局下一阶段的健康管理生态。该投资部门近日宣布，领投了Knownwell公司2500万美元的战略融资，后 者是一家以代谢健康为核心的初级医疗平台，致力于将肥胖症从单纯的药物治疗转向全面的慢性病管理模式。 Knownwell的商业模式与传统的GLP-1减重平台形成鲜明对比。这些传统平台通常依赖于快速开处方和高频订阅，侧重于药物销售和 用户增长；而Knownwell则采用由医生主导的综合管理模式，结合营养咨询、行为健康和远程监测，强调长期效果和患者体验。 这种转变反映了美国肥胖症治疗市场的结构性调整。根据Axios的报道，CVS Health Ventures的投资不仅是对Knownwell的资金支持， 更是对其"以患者为中心、以结果为导向"的模式的认可。 CVS Health Ventures的执行董事Alyssa Reisner表示："我们将其视为一种方法，可以转变全国范围内肥胖症的治疗方式。" 除了CVS Health Ventures之外，这轮2500万美元的融资还包括MassMutual Catalyst Fund、Inte ...

Core Insights - The article discusses two underperforming healthcare companies, Iovance Biotherapeutics and Teladoc Health, and evaluates their potential as contrarian investment opportunities [2][13]. Group 1: Iovance Biotherapeutics - Iovance Biotherapeutics is a small-cap biotech company known for its advanced melanoma treatment, Amtagvi, which was approved in February 2024 [3][4]. - Revenue from Amtagvi reached $109.3 million in the first half of 2025, more than tripling from the previous year [3]. - The company projects annual revenue of $250 million to $300 million, with a current market cap of $773 million [4]. - Iovance has received approval for Amtagvi in Canada and plans to expand into other countries, targeting a significant market due to the high mortality rate from melanoma in the U.S. [4][5]. - Amtagvi is also being investigated for treating other cancers, which could further enhance sales if clinical progress is made [6]. - The complexity of manufacturing and administering Amtagvi poses challenges, as it requires 34 days to prepare and can only be administered in specialized centers [6][7]. Group 2: Teladoc Health - Teladoc Health has experienced a decline in traction but maintains a large ecosystem with 102.4 million members in its integrated care segment, an 11% increase year-over-year [8]. - The company is addressing subscriber losses in its BetterHelp virtual therapy segment through acquisitions, including UpLift, which has insurance agreements covering 100 million potential patients [9][10]. - Teladoc's second-quarter revenue fell by 2% year-over-year to $631.9 million, but its established presence in telemedicine and international expansion efforts may support a recovery [11][12]. - Despite the risks, Teladoc is viewed as a more attractive investment option due to higher revenue and lower net losses compared to Iovance [13][15].

NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of LifeMD, Inc. (NASDAQ: LFMD). Shareholders who purchased shares of LFMD during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/lifemd-inc-loss-submission-form/?id=172059&from=3 CLASS PERIOD: May 7, 2025 to August ...

Core Insights - Hims & Hers Health, Inc. (HIMS) is transforming healthcare delivery through a vertically integrated, technology-driven model that combines telemedicine, data infrastructure, and AI-enabled personalization [1][7] - The company has made significant investments in AI, appointing Mo Elshenawy to lead the development of advanced healthcare algorithms and diagnostic tools, supported by an $870 million convertible notes offering [2][7] - Recent product innovations include a digitally managed hormone therapy program for men and AI-guided care personalization for women's hormonal health, positioning Hims & Hers as a leader in consumer-centric healthcare [3][7] Financial Performance - Hims & Hers shares have increased by 159.6% year-to-date, significantly outperforming the industry growth of 30.4% [6] - The Zacks Consensus Estimate for HIMS' 2025 earnings per share indicates a 122.2% improvement from 2024 [8] Valuation Metrics - HIMS' forward 12-month price-to-sales (P/S) ratio is 5.3X, which is lower than the industry's average of 5.9X but higher than its three-year median of 2.5X [10] - The company currently holds a Zacks Rank 4 (Sell) [12]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, of the upcoming lead plaintiff deadline for a securities class action lawsuit [1]. Group 1: Class Action Details - Investors who bought LifeMD securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 27, 2025 [3]. - The lawsuit claims that defendants made materially false and misleading statements regarding LifeMD's competitive position and financial guidance, leading to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has consistently ranked in the top 4 for securities class action settlements since 2013 and recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

Core Viewpoint - Teladoc (TDOC) is showing potential for short-term gains as it has crossed above the 20-day moving average, indicating a bullish trend [1][4]. Technical Analysis - TDOC has reached a key level of support and has been moving higher over the past four weeks, with an increase of 13.5% [1][4]. - The 20-day simple moving average is a significant indicator for short-term traders, as it smooths out price trends and provides more signals for trend reversals compared to longer-term averages [1][2]. Earnings Estimates - The company currently holds a Zacks Rank 1 (Strong Buy), suggesting a favorable outlook for continued price increases [4]. - In the past two months, no earnings estimates for TDOC have been lowered, while one estimate has been raised, contributing to a positive consensus estimate for the current fiscal year [4][5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased LifeMD, Inc. securities between May 7, 2025, and August 5, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - Investors who purchased LifeMD securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by October 27, 2025 [3] - The lawsuit alleges that defendants made materially false and misleading statements regarding LifeMD's competitive position and financial guidance, particularly concerning customer acquisition costs [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements since 2013 [4]